Scarica l'app Stockscreener
6.03
1.34%
0.08
Dopo l'orario di chiusura:
5.91
-0.12
-1.99%
Precedente Chiudi:
$5.95
Aprire:
$6.07
Volume 24 ore:
150.28K
Relative Volume:
0.77
Capitalizzazione di mercato:
$52.29M
Reddito:
$137.27M
Utile/perdita netta:
$-123.57M
Rapporto P/E:
-0.5474
EPS:
-11.016
Flusso di cassa netto:
$-102.89M
1 W Prestazione:
+3.61%
1M Prestazione:
-3.67%
6M Prestazione:
+36.43%
1 anno Prestazione:
-52.59%
Intervallo 1D:
$5.835
$6.07
Intervallo di 1 settimana:
$5.50
$6.22
Portata 52W:
$3.51
$16.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Nome
Karyopharm Therapeutics Inc
Settore
Industria
Telefono
617-658-0600
Indirizzo
85 WELLS AVENUE, NEWTON, MA
Confronta KPTI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
6.03 | 50.03M | 137.27M | -123.57M | -102.89M | -11.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | Ripresa | H.C. Wainwright | Buy |
| 2023-01-19 | Iniziato | Piper Sandler | Overweight |
| 2022-11-04 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Iniziato | Morgan Stanley | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-07-23 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-05 | Reiterato | Robert W. Baird | Outperform |
| 2019-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Reiterato | BofA/Merrill | Underperform |
| 2019-02-27 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Iniziato | B. Riley FBR | Buy |
| 2018-11-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2018-05-24 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-04-02 | Ripresa | Leerink Partners | Outperform |
| 2017-11-15 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2016-09-08 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-08-18 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-28 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Karyopharm Therapeutics Inc Borsa (KPTI) Ultime notizie
Can a trend reversal in Karyopharm Therapeutics Inc. lead to recovery2025 Earnings Impact & Weekly High Momentum Picks - newser.com
Price momentum metrics for Karyopharm Therapeutics Inc. explainedJuly 2025 Final Week & Free Weekly Chart Analysis and Trade Guides - newser.com
Sector ETF performance correlation with Karyopharm Therapeutics Inc.July 2025 Decliners & Verified Short-Term Plans - newser.com
Karyopharm Therapeutics Completes Financing Transactions for Growth - TipRanks
News impact scoring models applied to Karyopharm Therapeutics Inc.Portfolio Risk Summary & Stock Portfolio Risk Management - newser.com
Building trade automation scripts for Karyopharm Therapeutics Inc.2025 Institutional Moves & Fast Exit and Entry Strategy Plans - newser.com
How Recent Developments Are Shaping the Karyopharm Therapeutics Investment Story - Yahoo Finance
Karyopharm Therapeutics Shares Rise After HC Wainwright Upgrade - MarketScreener
KPTI Receives Upgrade to 'Buy' from HC Wainwright & Co. | KPTI S - GuruFocus
Karyopharm Therapeutics stock rating upgraded to Buy by H.C. Wainwright - Investing.com Canada
HC Wainwright & Co. Upgrades Karyopharm Therapeutics (KPTI) - Nasdaq
This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
HC Wainwright Upgrades Karyopharm Therapeutics to Buy From Neutral, $15 Price Target - MarketScreener
Is Karyopharm Therapeutics Inc. (25K0) stock a top hedge fund pickMarket Growth Summary & Precise Swing Trade Alerts - newser.com
What to expect from Karyopharm Therapeutics Inc. in the next 30 days2025 Breakouts & Breakdowns & Daily Profit Maximizing Trade Tips - newser.com
Using R and stats models for Karyopharm Therapeutics Inc. forecastingPortfolio Gains Summary & High Accuracy Trade Signal Alerts - newser.com
Heatmap analysis for Karyopharm Therapeutics Inc. and competitors2025 Price Momentum & Risk Controlled Stock Alerts - newser.com
Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price - MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
Will Karyopharm Therapeutics Inc. continue its uptrend2025 Geopolitical Influence & Advanced Technical Analysis Signals - newser.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Karyopharm Secures $100M Financing for Clinical Trials - MSN
KPTI: Piper Sandler Reiterates Overweight Rating, Lowers Price T - GuruFocus
Karyopharm Announces Strategic Financing Transactions to Support Growth, Extends Cash Runway into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis - MarketScreener
KPTI: Baird Lowers Price Target, Maintains Outperform Rating | K - GuruFocus
KPTI Strengthens Financial Position with $100M Capital Strategy - GuruFocus
Karyopharm Therapeutics stock price target lowered to $6 at Leerink Partners - Investing.com Canada
Karyopharm Raises $100M to Extend Cash Runway Through 2026Karyopharm Therapeutics (NASDAQ:KPTI) - Benzinga
Karyopharm Announces Strategic Financing Transactions to Support Growth - citybiz
Karyopharm announces strategic financing - The Pharma Letter
Karyopharm Therapeutics Inc. Provides Earnings Guidance for the Three Months Ended September 30, 2025 - MarketScreener
KPTI Projects Third Quarter Revenue and Cash Position - GuruFocus
Karyopharm secures $100 million in financing to extend cash runway By Investing.com - Investing.com Australia
Karyopharm stock falls after announcing $100 million financing deal By Investing.com - Investing.com Canada
Karyopharm secures $100 million in financing to extend cash runway - Investing.com India
Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis - PR Newswire
$100M Financial Flexibility — Karyopharm Extends Runway into Q2 2026; SENTRY top-line due March 2026 - Stock Titan
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Above 50-Day Moving AverageHere's Why - MarketBeat
Karyopharm Therapeutics Inc. announced that it expects to receive $23.748952 million in funding - MarketScreener
Myelofibrosis Market Overview: Epidemiology, Therapies, - openPR.com
Is Karyopharm Therapeutics Inc. stock oversold or undervaluedEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Will Karyopharm Therapeutics Inc. rebound enough to break evenGlobal Markets & AI Driven Price Predictions - newser.com
Measuring Karyopharm Therapeutics Inc.’s beta against major indicesQuarterly Trade Report & AI Driven Stock Movement Reports - newser.com
Selinexor Study Withdrawal: Implications for Karyopharm Therapeutics - TipRanks
Using data filters to optimize entry into Karyopharm Therapeutics Inc. - newser.com
How Karyopharm Therapeutics Inc. (25K0) stock trades pre earningsJuly 2025 Institutional & Verified Trade Idea Suggestions - newser.com
Multi asset correlation models including Karyopharm Therapeutics Inc.July 2025 Closing Moves & Safe Entry Zone Tips - newser.com
Karyopharm Therapeutics Inc Azioni (KPTI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Karyopharm Therapeutics Inc Azioni (KPTI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Paulson Richard A. | President and CEO |
Sep 15 '25 |
Sale |
6.43 |
1,257 |
8,083 |
84,046 |
| Mano Michael | SVP, General Counsel&Secretary |
Sep 15 '25 |
Sale |
6.43 |
234 |
1,505 |
21,425 |
| Poulton Stuart | EVP, Chief Development Officer |
Sep 15 '25 |
Sale |
6.43 |
401 |
2,578 |
27,710 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Sep 15 '25 |
Sale |
6.43 |
408 |
2,623 |
29,390 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
Sep 15 '25 |
Sale |
6.43 |
325 |
2,090 |
35,856 |
| Abate Kristin | Chief Accounting Officer |
Sep 15 '25 |
Sale |
6.43 |
23 |
148 |
10,408 |
| Abate Kristin | Chief Accounting Officer |
Sep 03 '25 |
Sale |
6.78 |
12 |
81 |
9,463 |
| Poulton Stuart | EVP, Chief Development Officer |
Jul 29 '25 |
Sale |
4.37 |
191 |
835 |
27,223 |
| Abate Kristin | Chief Accounting Officer |
Jul 22 '25 |
Sale |
4.00 |
238 |
952 |
9,475 |
| Paulson Richard A. | President and CEO |
May 06 '25 |
Sale |
7.12 |
236 |
1,680 |
82,503 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):